“Another study failed to show improvements in hearing compared to the placebo group, but the company attributes that result to flaws in the design of the trial.”
MIT News ran a glowing profile of a Nasdaq-listed spinout founded by MIT people. The headline says reversing hearing loss. Paragraphs later, one trial showed nothing over placebo. The company blames the trial design, and everything now rides on a 124-person study that hasn’t reported.